How does this work? Shots administered to teenagers??
How does this work? Shots administered to teenagers??
Investing so late in the weight loss rush. Three to four drugs are on the market and semaglutide patents will expire soon.
my thoughts on the AstraZeneca deal. It seems to me that AZ is already really invested in Chinese biotech sector. This will simply allow them to further use the Chinese drug development pipeline to get ahead.
I think long term, the American biotech scene will get wiped out.
Investing so late in the weight loss rush. Three to four drugs are on the market and semaglutide patents will expire soon.
Parents expiring should lead to push towards generics, I doubt the viability of launching a new molecule which might have marginally better efficacy than ozempic.There's a rush precisely because the patents are expiring.
And I suspect the overall amounts will largely be royalties dependent on actual sales.
MGI licensed gene sequencing tech to Swiss company. MGI is rapidly gaining overseas market share in gene sequencers after Illumina settled their IP disputes and paid MGI 325million in 2022.
MGI is repeating in sequencers what Hesai did in lidars
wow exclusive and perpetual?The agreement grants Swiss Rockets a perpetual, transferable and sublicensable, freedom-to-operate licence for the United States of America, Europe, Latin America, Africa and Central Asia. There is an option to expand the rights into the Asia-Pacific region in 2026. The agreement covers the patents and other intellectual property necessary for development, manufacturing, and sales of the next-generation CoolMPS sequencing platform, which will provide faster, cheaper, and more accurate whole genome sequencing and other omics tests. The agreement includes payments linked to technology transfer and revenue-based royalties.
I don’t think so. They don’t allow live human medicine experimentations in the PRC.China's development of new drugs is only half the cost of the US, but twice the speed. China filed more drug patents this year than the U.S. That’s never happened in history. Five years ago, the split was 90%-10%. ...
Albert Bourla, Pfizer CEO